[1] Kopeć G., Kurzyna M., Mroczek E. et al. Characterization of
Patients with Pulmonary Arterial Hypertension: Data from the Polish
Registry of Pulmonary Hypertension (BNP-PL). J Clin Med. 2020 Jan
8;9(1). pii: E173.
[2] Siennicka A., Darocha S., Banaszkiewicz M. et al. Treatment of
chronic thromboembolic pulmonary hypertension in a multidisciplinary
team. Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619891529.
[3] Travadi JN, Patole SK: Phosphodiesterase inhibitors for
persistent pulmonary hypertension of the newborn: A review. Pediatr
Pulmonol 2003; 36: 529–535.
[4] Nair J, Lakshminrusimha S, Update on PPHN: mechanisms and
treatment. Semin Perinatol. 2014 Mar;38(2):78-91. doi:
10.1053/j.semperi.2013.11.004.
[5] Zalecenia Polskiego Towarzystwa Neonatologicznego. Standardy
opieki medycznej nad noworodkiem w Polsce. Wydanie II (2017),
zaktualizowane i uzupełnione. [Recommendations of the Polish Society
of Neonatology. Standards of medical care for neonates in Poland. Second
edition (2017), revised and updated.] Warsaw, PTN&Media-Press Sp. z
o.o. 2017, 171-176
[6] Medicinal product dossier:
INOmax,
INN-nitric oxide
[7] Lakshminrusimha S, Porta NF, Farrow KN, Chen B, Gugino SF, Kumar
VH, et al. Milrinone enhances relaxation to prostacyclin and iloprost in
pulmonary arteries isolated from lambs with persistent pulmonary
hypertension of the newborn. Pediatric critical care medicine: a journal
of the Society of Critical Care Medicine and the World Federation of
Pediatric Intensive and Critical Care Societies. 2009;10:106–12.
[8] Walas W, Borszewska- Kornacka M, Świetliński J - Zespół
przetrwałego nadciśnienia płucnego u noworodków. Algorytm leczenia.
[Persisten pulmonary hypertension of the newborn. A therapeutic
algorithm.] MediPage, 2012,11-14
[9] Rawat M., Chandrasekharan P.K., Williams A., Gugino S.,
Koenigsknecht C., Swartz D., Ma C.X., Mathew B., Nair J.,
Lakshminrusimha S. Oxygen saturation index and severity of hypoxic
respiratory failure. Neonatology. 2015;107:161–166.
[7] Khemani
RG1, Thomas NJ, Venkatachalam V, Scimeme JP, Berutti T, Schneider
JB, Ross PA, Willson DF, Hall MW, Newth CJ; Comparison of SpO2 to PaO2
based markers of lung disease severity for children with acute lung
injury. Pediatric Acute Lung Injury and Sepsis Network Investigators
(PALISI). Crit Care
Med. 2012 Apr;40(4):1309-16.
[8] McNamara PJ, Shivananda SP, Sahni M, Freeman D, Taddio A.
Pharmacology of milrinone in neonates with persistent pulmonary
hypertension of the newborn and suboptimal response to inhaled nitric
oxide. Pediatric critical care medicine: a journal of the Society of
Critical Care Medicine and the World Federation of Pediatric Intensive
and Critical Care Societies. 2013;14:74–84.
[9] Bassler D, Choong K, McNamara P, Kirpalani H. Neonatal
persistent pulmonary hypertension treated with milrinone: four case
reports. Biol Neonate. 2006;89:1–5.
[10] McNamara PJ, Laique F, Muang-In S, Whyte HE. Milrinone improves
oxygenation in neonates with severe persistent pulmonary hypertension of
the newborn. J Crit Care. 2006;21:217–22
[11] Ho J.J., Rasa G.: Magnesium sulfate for persistent pulmonary
hypertension of the newborn. Cochrane Database Syst Rev 2007,
18:CD005588.
[12] Boo N.Y., Rohana J., Yong S.C. et al.: Inhaled nitric oxide and
intravenous magnesium sulphate for the treatment of persistent pulmonary
hypertension of the newborn. Singapore Med J 2010, 51:144–150.
[13] SatyanLakshminrusimhaMDBobbyMathewMRCPCorinne L.LeachMD, PhD
Seminars in Perinatology Volume 40, Issue 3, April 2016, Pages 160-173
[14] Bassler D, Choong K, McNamara PJ, Kirpalani H. Neonatal
persistent pulmonary hypertension treated with milrinone: four case
reports. Biol Neonate 2006; 89: 1-5.
[15] Medicinal product dossier: Corotrope